Endocrine Abstracts

Introduction: Treatment with anti-TNFα therapy such as infliximab may improve growth in children with CD but the extent of improvement in growth and its relationship to pubertal progress and changes in glucocorticoid therapy are unclear.Aim: A retrospective study of growth, puberty and disease activity over the 6 months prior (T−6) to starting infliximab, at baseline (T0) and for the following 6 months (T+6) in CD. Results are expressed as med...